Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.11 EUR
−3.52 M EUR
4.64 M EUR
33.04 M
About ABIONYX PHARMA
Sector
CEO
Cyrille Tupin
Headquarters
Balma
Website
Founded
2005
ISIN
FR0012616852
FIGI
BBG008F939V9
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. It specializes in the development of treatment for cardiovascular and metabolic disorders. The company was founded by Jean-Louis Dasseux and William F. Brinkerhoff on March 24, 2005 and is headquartered in Balma, France.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 609 is 1.29 EUR — it has increased by 1.42% in the past 24 hours. Watch ABIONYX PHARMA SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ABIONYX PHARMA SA stocks are traded under the ticker 609.
609 stock has risen by 9.69% compared to the previous week, the month change is a 11.98% rise, over the last year ABIONYX PHARMA SA has showed a 2.87% increase.
We've gathered analysts' opinions on ABIONYX PHARMA SA future price: according to them, 609 price has a max estimate of 11.50 EUR and a min estimate of 11.50 EUR. Watch 609 chart and read a more detailed ABIONYX PHARMA SA stock forecast: see what analysts think of ABIONYX PHARMA SA and suggest that you do with its stocks.
609 stock is 1.42% volatile and has beta coefficient of −0.87. Track ABIONYX PHARMA SA stock price on the chart and check out the list of the most volatile stocks — is ABIONYX PHARMA SA there?
Today ABIONYX PHARMA SA has the market capitalization of 46.81 M, it has decreased by −6.74% over the last week.
Yes, you can track ABIONYX PHARMA SA financials in yearly and quarterly reports right on TradingView.
ABIONYX PHARMA SA is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
609 net income for the last half-year is −2.09 M EUR, while the previous report showed −1.27 M EUR of net income which accounts for −64.41% change. Track more ABIONYX PHARMA SA financial stats to get the full picture.
No, 609 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 30, 2024, the company has 61.00 employees. See our rating of the largest employees — is ABIONYX PHARMA SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABIONYX PHARMA SA EBITDA is −4.77 M EUR, and current EBITDA margin is −108.90%. See more stats in ABIONYX PHARMA SA financial statements.
Like other stocks, 609 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABIONYX PHARMA SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABIONYX PHARMA SA technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABIONYX PHARMA SA stock shows the buy signal. See more of ABIONYX PHARMA SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.